QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 neurobo-pharmaceuticals-q2-eps-185-misses-112-estimate

NeuroBo Pharmaceuticals (NASDAQ:NRBO) reported quarterly losses of $(1.85) per share which missed the analyst consensus estimat...

 neurobo-pharmaceuticals-together-with-dong-a-st-and-immunoforge-announces-joint-research-agreement-to-develop-a-long-acting-once-monthly-formulation-of-da-1726-for-the-treatment-of-obesity-financial-terms-of-the-agreement-were-not-disclosed

Collaboration to Leverage ImmunoForge's ELP Platform Technology Which Can Increase the Half-Life of a Drug by up to 200 Tim...

 watching-neurobo-pharmaceuticals-zacks-small-cap-research-gives-stock-22-price-valuation

https://s27.q4cdn.com/906368049/files/News/2024/Zacks_SCR_Research_07012024_NRBO_Bautz.pdf

 dong-a-st-10-buys-254m-shares-of-neurobo-pharmaceuticals-at-avg-price-of-313-total-value-of-79643789

- Form4

 reported-earlier-neurobos-novel-drug-shows-results-for-weight-loss-at-ada-2024

 NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company focused on the transformation of cardiomet...

 neurobo-pharmaceuticals-stock-slides-despite-animal-study-showing-wegvoy-liver-fibrosis-success

NeuroBo says DA-1241 data shows improved liver fibrosis and additive hepatoprotective effects when combined with semaglutide.

 neurobo-pharmaceuticals-reports-pre-clinical-data-suggesting-da-1241-combined-with-semaglutide-improves-liver-fibrosis-and-demonstrates-additive-hepatoprotective-effects-in-pre-clinical-mash-models-compared-to-either-treatment-alone

Data Will be Presented in Two Posters at the EASL Congress 2024

 neurobo-pharmaceuticals-q1-2024-gaap-eps-132-misses-110-estimate

NeuroBo Pharmaceuticals (NASDAQ:NRBO) reported quarterly losses of $(1.32) per share which missed the analyst consensus estimat...

 maxim-group-initiates-coverage-on-neurobo-pharmaceuticals-with-buy-rating-announces-price-target-of-10

Maxim Group analyst Jason McCarthy initiates coverage on NeuroBo Pharmaceuticals (NASDAQ:NRBO) with a Buy rating and announc...

 neurobo-to-present-latest-pre-clinical-data-on-cardiometabolic-assets-da-1241-and-da-1726-targeting-mash-and-obesity-at-scientific-conferences-in-june

NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company focused on the transformation of cardiometa...

 neurobo-pharmaceuticals-files-for-mixed-shelf-offering-of-up-to-150m

https://www.sec.gov/Archives/edgar/data/1638287/000155837024005018/tmb-20240412xs3.htm 

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION